Cargando…

Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment

The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Chiara, Turchinovich, Andrey, Feisst, Manuel, Riedel, Fabian, Haßdenteufel, Kathrin, Scharli, Philipp, Hartkopf, Andreas D., Brucker, Sara Y., Michel, Laura, Burwinkel, Barbara, Schneeweiss, Andreas, Wallwiener, Markus, Deutsch, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455626/
https://www.ncbi.nlm.nih.gov/pubmed/36076930
http://dx.doi.org/10.3390/ijms23179535
_version_ 1784785620270317568
author Fischer, Chiara
Turchinovich, Andrey
Feisst, Manuel
Riedel, Fabian
Haßdenteufel, Kathrin
Scharli, Philipp
Hartkopf, Andreas D.
Brucker, Sara Y.
Michel, Laura
Burwinkel, Barbara
Schneeweiss, Andreas
Wallwiener, Markus
Deutsch, Thomas M.
author_facet Fischer, Chiara
Turchinovich, Andrey
Feisst, Manuel
Riedel, Fabian
Haßdenteufel, Kathrin
Scharli, Philipp
Hartkopf, Andreas D.
Brucker, Sara Y.
Michel, Laura
Burwinkel, Barbara
Schneeweiss, Andreas
Wallwiener, Markus
Deutsch, Thomas M.
author_sort Fischer, Chiara
collection PubMed
description The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC.
format Online
Article
Text
id pubmed-9455626
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94556262022-09-09 Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment Fischer, Chiara Turchinovich, Andrey Feisst, Manuel Riedel, Fabian Haßdenteufel, Kathrin Scharli, Philipp Hartkopf, Andreas D. Brucker, Sara Y. Michel, Laura Burwinkel, Barbara Schneeweiss, Andreas Wallwiener, Markus Deutsch, Thomas M. Int J Mol Sci Article The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC. MDPI 2022-08-23 /pmc/articles/PMC9455626/ /pubmed/36076930 http://dx.doi.org/10.3390/ijms23179535 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fischer, Chiara
Turchinovich, Andrey
Feisst, Manuel
Riedel, Fabian
Haßdenteufel, Kathrin
Scharli, Philipp
Hartkopf, Andreas D.
Brucker, Sara Y.
Michel, Laura
Burwinkel, Barbara
Schneeweiss, Andreas
Wallwiener, Markus
Deutsch, Thomas M.
Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
title Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
title_full Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
title_fullStr Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
title_full_unstemmed Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
title_short Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
title_sort circulating mir-200 family and ctcs in metastatic breast cancer before, during, and after a new line of systemic treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455626/
https://www.ncbi.nlm.nih.gov/pubmed/36076930
http://dx.doi.org/10.3390/ijms23179535
work_keys_str_mv AT fischerchiara circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT turchinovichandrey circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT feisstmanuel circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT riedelfabian circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT haßdenteufelkathrin circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT scharliphilipp circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT hartkopfandreasd circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT bruckersaray circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT michellaura circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT burwinkelbarbara circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT schneeweissandreas circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT wallwienermarkus circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment
AT deutschthomasm circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment